Eli Lilly entered into research and development deals. The deal with MorphoSys allows Eli Lilly to gain access to MorphoSys' HuCAL GOLD® technology to develop therapeutic antibodies. The second Lilly collaboration was with GlycoFi to initiate research programs to optimize the glycosylation of Lilly’s biological therapeutics.